Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ

Imagem de Miniatura
Arquivos
art_AGUIAR_Basal_cytokeratin_as_a_potential_marker_of_low_2013.PDF (1.38 MB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2013
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
BACCHI, Carlos E.
Citação
CLINICS, v.68, n.5, p.638-643, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: Biological markers that predict the development of invasive breast cancer are needed to improve personalized therapy for patients diagnosed with ductal carcinoma in situ. We investigated the role of basal cytokeratin 5/6 in the risk of invasion in breast ductal carcinoma in situ. METHODS: We constructed tissue microarrays using 236 ductal carcinoma in situ samples: 90 pure samples (group 1) and 146 samples associated with invasive carcinoma (group 2). Both groups had similar nuclear grades and were obtained from patients of similar ages. The groups were compared in terms of estrogen (ER) and progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) expression, cytokeratin 5/6 immunostaining, human epidermal growth factor receptor 1 (EGFR) membrane staining and molecular subtype, as indicated by their immunohistochemistry profiles. RESULTS: ER/PR-negative status was predictive of invasion, whereas HER2 superexpression and cytokeratin 5/6-positive status were negatively associated with invasion. Among the high-grade ductal carcinoma in situ cases, a triple-positive profile (positive for estrogen receptor, progesterone receptor, and HER2) and cytokeratin 5/6 expression by neoplastic cells were negatively associated with invasion. In the low-grade ductal carcinoma in situ subgroup, only cytokeratin 5/6 expression exhibited a negative association with the probability of invasion. CONCLUSION: The immunohistochemical expression of cytokeratin 5/6 by ductal carcinoma in situ epithelial cells may provide clinically useful information regarding the risk of progression to invasive disease.
Palavras-chave
Breast Cancer, Ductal Carcinoma In Situ, Immunohistochemistry, Prognosis, Basal Cytokeratin
URI
https://observatorio.fm.usp.br/handle/OPI/2180
Referências
  1. Allred D. Craig, 2010, Journal of the National Cancer Institute Monographs, P134, DOI 10.1093/jncimonographs/lgq035
  2. Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127
  3. Bhargava R, 2009, INT J CLIN EXP PATHO, V2, P444
  4. Bijker Nina, 2010, Journal of the National Cancer Institute Monographs, P178, DOI 10.1093/jncimonographs/lgq025
  5. Bryan BB, 2006, MODERN PATHOL, V19, P617, DOI 10.1038/modpathol.3800570
  6. Cheang MCU, 2009, J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
  7. Chu PGG, 2002, MODERN PATHOL, V15, P6, DOI 10.1038/modpathol.3880483
  8. Collado MV, 2010, CLIN TRANSL ONCOL, V12, P499, DOI 10.1007/s12094-010-0543-3
  9. Collins LC, 2005, MODERN PATHOL, V18, P615, DOI 10.1038/modpathol.3800360
  10. DAIRKEE SH, 1987, LANCET, V1, P514
  11. Ernster VL, 2002, J NATL CANCER I, V94, P1546
  12. Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041
  13. Han K, 2012, CLIN ONCOL-UK, V24, P183, DOI 10.1016/j.clon.2011.09.008
  14. Harada S, 2011, J SURG ONCOL, V104, P458, DOI 10.1002/jso.21973
  15. Lari SA, 2011, J CANCER, V2, P232, DOI 10.7150/jca.2.232
  16. Liu ZB, 2009, TUMORI, V95, P53
  17. Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
  18. Livasy CA, 2007, HUM PATHOL, V38, P197, DOI 10.1016/j.humpath.2006.08.017
  19. Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226
  20. MOLL R, 1983, DIFFERENTIATION, V23, P256
  21. Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
  22. Ottesen GL, 2000, BREAST CANCER RES TR, V60, P219, DOI 10.1023/A:1006453420088
  23. Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
  24. Rakovitch E, 2012, BRIT J CANCER, V106, P1160, DOI 10.1038/bjc.2012.41
  25. Rudloff U, 2010, ANN SURG, V251, P583, DOI 10.1097/SLA.0b013e3181b5931e
  26. Schnitt Stuart J., 2010, Journal of the National Cancer Institute Monographs, P158, DOI 10.1093/jncimonographs/lgq031
  27. Sgroi DC, 2010, ANNU REV PATHOL-MECH, V5, P193, DOI 10.1146/annurev.pathol.4.110807.092306
  28. Smith BL, 2010, MODERN PATHOL, V23, pS33, DOI 10.1038/modpathol.2010.53
  29. Solin Lawrence J., 2010, Journal of the National Cancer Institute Monographs, P187, DOI 10.1093/jncimonographs/lgq020
  30. Son BK, 2011, J BREAST CANCER, V14, P301, DOI 10.4048/jbc.2011.14.4.301
  31. Steinman S, 2007, ANN CLIN LAB SCI, V37, P127
  32. Tavassoli F, 2003, IARC WHO CLASSIFICAT
  33. Thike AA, 2010, AM J SURG PATHOL, V34, P956, DOI 10.1097/PAS.0b013e3181e02f45
  34. Veronesi P, 2005, BREAST, V14, P520, DOI 10.1016/j.breast.2005.08.007
  35. Wang SY, 2011, BREAST CANCER RES TR, V127, P1, DOI 10.1007/s10549-011-1387-4
  36. WETZELS RHW, 1989, AM J PATHOL, V134, P571
  37. Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
  38. Yen TWF, 2005, J AM COLL SURGEONS, V200, P516, DOI 10.1016/j.jamcollsurg.2004.11.012
  39. Zhou WJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-653

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03